Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging evidence indicates that the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is activated, which results in a cytokine storm at the late stage of COVID-19. Autophagy regulation is involved in the infection and replication of SARS-CoV-2 at the early stage and the inhibition of NLRP3 inflammasome-mediated lung inflammation at the late stage of COVID-19. Here, we discuss the autophagy regulation at different stages of COVID-19. Specifically, we highlighted the therapeutic potential of autophagy activators in COVID-19 by inhibiting the NLRP3 inflammasome, thereby avoiding the cytokine storm. We hope this review provides enlightenment for the use of autophagy activators targeting the inhibition of the NLRP3 inflammasome, specifically the combinational therapy of autophagy modulators with the inhibitors of the NLRP3 inflammasome, antiviral drugs, or anti-inflammatory drugs in the fight against COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, NLRP3 inflammasome, Lung inflammation, Autophagy regulation, 【초록키워드】 Coronavirus disease 2019, Cytokine storm, coronavirus, therapy, antiviral drugs, Infection, Infectious disease, autophagy, Inflammasome, inhibitor, early stage, NLRP3, Evidence, protein 3, acute respiratory syndrome, Regulation, therapeutic potential, Stage, anti-inflammatory drug, late stage, replication of SARS-CoV-2, caused, involved, provide, activated, indicate, inhibiting, the cytokine storm, 【제목키워드】 autophagy, NLRP3, Regulation, targeting,